Abstract 810P
Background
Recent studies suggested that tumor size reduction by means of pc prior to radical surgery might improve survival outcomes (SO) in CC pts. Whether pc has a beneficial effect in CC pts undergoing radical surgery in the form of total mesometrial resection (TMMR) is unclear. Because of the prevention of intraoperative tumor spillage by performing a closed colpotomy is essential to all TMMR, we hypothesized that pc would not affect SO in TMMR pts.
Methods
We performed a retrospective analysis of data which was collected in the Leipzig Mesometrial Resection trial. All pts had been treated for primary CC staged IB1 – IVA (2018-FIGO) by open abdominal hysterectomy performed as total or extended mesometrial resection (TMMR/EMMR). Recurrence-free (RFS) and overall survival (OAS) were analyzed. Cox proportional hazards regression models (Cox-R) were built to define the effect of pc. RFS and OAS within the conization group were analyzed to determine whether there is a difference between R0 (tumor removed completely) and R1 (tumor removed incompletely) conization.
Results
542 pts were included, of which 202 had received pc. After 1:1 propensity score matching including 163 pts with conization and 163 controls, pc was associated with significantly increased RFS (95.6% vs. 82.3%, HR 3.2, p<0.001) and OAS (99.2% vs. 85.6%, HR 6.4, p<0.001). In multivariable Cox-R pc was the only independent factor affecting RFS (HR 0.3, p<0.01). Analysis of the martingale residuals in a Cox regression null-model only including tumor-size revealed a continuous increase of recurrence risk with each increment in maximum tumor diameter for pts without pc, reaching a recurrence risk of 45% at a tumor size of 70 mm. In contrast, the recurrence risk for pts who had undergone pc plateaued at 12% at a tumor size of 37 mm. The sub analysis between R0 and R1 conization pts showed no difference in RFS and OAS.
Conclusions
In this study, pc was independently associated with improved survival in CC pts treated with TMMR/EMMR. Since intraoperative tumor spillage was avoided by closed colpotomy, factors other than the prevention of local tumor cell dissemination might play a role in improving survival. There is a need of further research to understand the concrete effect of pc to tumor biology.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
UKL-Universitätsklinikum Leipzig.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
628P - Immunotherapy in mismatch repair-deficient metastatic colorectal cancer: Long-term outcome and novel predictive markers
Presenter: Amos Stemmer
Session: Poster session 11
629P - First results of the french prospective cohort of colorectal cancers with microsatellite instability (COLOMIN2)
Presenter: David Tougeron
Session: Poster session 11
630P - Determining a prognostic score using imaging to assess the benefit of combo anti-PD1 + anti-CTL4 vs anti-PD1 in patients with metastatic MSI/dMMR colorectal cancer (mCRC MSI)
Presenter: Remy Barbe
Session: Poster session 11
631P - Using the unique somatic mutation profile of POLE loss of proof-reading mutation helps in selection of patients who may benefit from immunotherapy
Presenter: Giulia Maddalena
Session: Poster session 11
632P - Predictive value of C-reactive protein (CRP) in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) patients given first-line alternating short-course oxaliplatin-based chemotherapy (FLOX) and nivolumab
Presenter: Sebastian Meltzer
Session: Poster session 11
633P - Genomic alterations in SPEN predict outcome of immune checkpoint therapy in gastrointestinal cancer
Presenter: Changxiong Wu
Session: Poster session 11
634P - The ave-rec phase II trial of PD-L1/PD-1 blockade with avelumab plus chemoradiotherapy for resectable ESMO high risk rectal cancers
Presenter: Michael Michael
Session: Poster session 11
635P - Avelumab (AVE) combined with cetuximab (CET) and irinotecan (IRI) for the treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): The AVETUXIRI phase II study
Presenter: Marc van den Eynde
Session: Poster session 11